Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Belimumab IV vs SC Auto-injector in Healthy Chinese Participants
NCT04136145Phase 1Completed
- Sponsor
- GSK
- Start
- Oct 2019
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of belimumab in systemic lupus erythematosus (SLE) (2 arms), sponsored by GSK. Primary endpoints: Serum Concentration of Belimumab Following Intravenous Administration at 1680 hours and Serum Concentration of Belimumab Following Subcutaneous Administration at 1680 hours. Started Oct 2019; status: completed.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04136145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04136145.